ES2085983T3 - Antagonistas de anticuerpos de la interleuquina-4 humana. - Google Patents

Antagonistas de anticuerpos de la interleuquina-4 humana.

Info

Publication number
ES2085983T3
ES2085983T3 ES91902038T ES91902038T ES2085983T3 ES 2085983 T3 ES2085983 T3 ES 2085983T3 ES 91902038 T ES91902038 T ES 91902038T ES 91902038 T ES91902038 T ES 91902038T ES 2085983 T3 ES2085983 T3 ES 2085983T3
Authority
ES
Spain
Prior art keywords
antibodies
binding
antagonists
receptors
interleuquina
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91902038T
Other languages
English (en)
Inventor
Lata Ramanathan
Gail F Seelig
Paul P Trotta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ES2085983T3 publication Critical patent/ES2085983T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

ANTAGONISTAS DE ANTICUERPOS DE LA INTERLEUKINA-4 HUMANA ESTA INVENCION PRESENTA DOS TIPOS DE ANTAGONISTAS DE ANTICUERPOS DEL ENLACE DE LA IL-4 HUMANA A RECEPTORES CELULARES. ALGUNOS DE LOS ANTAGONISTAS SE ENLAZAN A REGIONES ESPECIFICAS DE LA IL-4 QUE SE PIENSA ESTAN RELACIONADOS CON LAS INTERACCIONES ENTRE LA IL-4 Y SUS RECEPTORES. DEBIDO A ESTE ENLACE ESPECIFICO MEDIANTE LOS ANTICUERPOS A LA IL-4, EL ENLACE DE LA IL-4 A LOS RECEPTORES SE INHIBE SUSTANCIALMENTE. LOS OTROS ANTAGONISTAS DE ANTICUERPOS DE LA INVENCION SON ANTICUERPOS ANTI-IDIOTIPICOS QUE, AL NO TENER UNA ACTIVIDAD IL-4, PARECEN IMITAR A LA IL-4 Y COMPETIR DIRECTAMENTE CON ELLA PARA UNIRSE A LOS RECEPTORES CELULARES. TAMBIEN SE PRESENTAN LOS POLIPEPTIDOS UTILIZADOS PARA HACER LOS ANTAGONISTAS DE ANTICUERPOS, JUNTO CON LOS METODOS PARA UTILIZAR LOS ANTAGONISTAS PARA INHIBIR EL ENLACE DE LA IL-4 A SUS RECEPTORES CELULARES.
ES91902038T 1989-12-20 1990-12-18 Antagonistas de anticuerpos de la interleuquina-4 humana. Expired - Lifetime ES2085983T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45357089A 1989-12-20 1989-12-20

Publications (1)

Publication Number Publication Date
ES2085983T3 true ES2085983T3 (es) 1996-06-16

Family

ID=23801108

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91902038T Expired - Lifetime ES2085983T3 (es) 1989-12-20 1990-12-18 Antagonistas de anticuerpos de la interleuquina-4 humana.

Country Status (26)

Country Link
US (1) US6358509B1 (es)
EP (1) EP0506826B1 (es)
JP (1) JPH0730116B2 (es)
KR (1) KR960016862B1 (es)
AT (1) ATE136906T1 (es)
AU (1) AU639754B2 (es)
CA (1) CA2071908C (es)
CZ (1) CZ283050B6 (es)
DE (1) DE69026627T2 (es)
DK (1) DK0506826T3 (es)
ES (1) ES2085983T3 (es)
FI (1) FI104180B1 (es)
GR (1) GR3020325T3 (es)
HU (1) HU215245B (es)
IE (1) IE74708B1 (es)
IL (1) IL96714A0 (es)
MX (1) MX9203401A (es)
MY (1) MY106507A (es)
NO (1) NO922457D0 (es)
NZ (1) NZ236511A (es)
OA (1) OA09704A (es)
PT (1) PT96230B (es)
SK (1) SK279933B6 (es)
TW (1) TW221675B (es)
WO (1) WO1991009059A1 (es)
ZA (1) ZA9010190B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714146A (en) * 1992-08-26 1998-02-03 Board Of Regents Of The University Of Washington IL-4 bone therapy
ZA946765B (en) 1993-09-02 1996-02-15 Dartmouth College Methods of prolonged suppression of humoral immunity
US5928904A (en) * 1993-09-07 1999-07-27 Smithkline Beecham Corporation DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US20020193575A1 (en) 1993-09-07 2002-12-19 Smithkline Beecham P.L.C. Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5914110A (en) * 1993-09-07 1999-06-22 Smithkline Beecham Corporation Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
UA48940C2 (uk) * 1993-09-07 2002-09-16 Смітклайн Бічам Корпорейшн Рекомбінатні il4 антитіла, які використовуються для лікування il4-опосередкованих порушень
US5597710A (en) * 1994-03-10 1997-01-28 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US5705154A (en) * 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
IL126714A (en) * 1997-02-28 2010-12-30 Enzo Therapeutics Inc Use of cells, organs or components thereof for the preparation of a pharmaceutical composition for establishing selective immune downregulation
ES2277460T3 (es) 1998-12-14 2007-07-01 Genetics Institute, Llc Cadena del receptor de la citoquina.
US7553487B2 (en) 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
DE60135170D1 (de) * 2000-04-06 2008-09-18 Fujifilm Corp Farbstoffkomplex und optisches Informationsaufzeichnungsmedium
DE16192152T1 (de) 2000-05-26 2020-08-06 Immunex Corporation Verwendung von interleukin-4 rezeptor (il-4r) antikörpern und zusammensetzungen davon
WO2002004009A2 (en) * 2000-07-12 2002-01-17 Immunex Corporation Method for treating cancer using an interleukin- 4 antagonist
US20030170258A1 (en) * 2001-05-09 2003-09-11 Enzo Therapeutics, Inc. Novel processes implementing selective immune down regulation (SIDR)
FR2838444B1 (fr) 2002-04-10 2016-01-01 Neovacs Nouveaux peptides et leur application en therapeutique
US20070104710A1 (en) * 2002-06-28 2007-05-10 Domants Limited Ligand that has binding specificity for IL-4 and/or IL-13
WO2004003156A2 (en) * 2002-07-01 2004-01-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Il-21 as a regulator of immunoglobin production
US20110223168A1 (en) * 2002-12-27 2011-09-15 Greg Winter Ligand that has binding specificity for il-4 and/or il-13
WO2004096849A2 (en) * 2003-04-25 2004-11-11 University Of Manitoba Peptide-based cytokine/chemokine vaccines against allergy
ATE548388T1 (de) 2003-11-07 2012-03-15 Immunex Corp An den interleukin-4-rezeptor bindende antikörper
ES2533084T3 (es) 2003-12-23 2015-04-07 Genentech, Inc. Tratamiento del cáncer con anticuerpos monoclonales anti-IL 13 novedosos
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
PE20060560A1 (es) * 2004-08-03 2006-06-27 Novartis Ag Anticuerpos de interleucina-4 humana
JP5750373B2 (ja) * 2008-11-17 2015-07-22 コーベンハブンス ウニベルシテト 慢性炎症性応答の調節および自己免疫疾患の処置のためのｉｌ−４由来ペプチド
RU2624027C2 (ru) 2010-04-23 2017-06-30 Дженентек, Инк. Получение гетеромультимерных белков
MX355255B (es) 2011-02-04 2018-04-11 Genentech Inc Variantes de fc y métodos para su producción.
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
WO2014165771A2 (en) * 2013-04-05 2014-10-09 Genentech, Inc. Anti-il-4 antibodies and bispecific antibodies and uses thereof
JP6546178B2 (ja) 2013-09-13 2019-07-17 ジェネンテック， インコーポレイテッド 細胞株中の宿主細胞タンパク質及び組換えポリペプチド産物を検出及び定量化するための組成物並びに方法
NZ756750A (en) 2013-09-13 2022-05-27 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
RU2758092C1 (ru) * 2018-02-01 2021-10-26 Бэйцзин Кавин Текнолоджи Шеа-Холдинг Ко., Лтд. АНТИТЕЛО К IL-4Rα И ЕГО ПРИМЕНЕНИЕ

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT83761B (pt) * 1985-11-19 1989-06-30 Schering Biotech Corp Metodo para a producao de interleuquina-4 de mamifero
US5041381A (en) * 1986-07-03 1991-08-20 Schering Corporation Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
US5013824A (en) * 1985-11-19 1991-05-07 Schering Corporation Human interleukin-4 peptides and conjugates thereof
ZA872781B (en) 1986-05-19 1987-10-05 Immunology Ventures B-cell stimulating factor
ATE93144T1 (de) * 1988-02-02 1993-09-15 Schering Biotech Corp Methode zur verminderung der immunglobulin-ereaktion.

Also Published As

Publication number Publication date
EP0506826A1 (en) 1992-10-07
HU215245B (hu) 1998-11-30
JPH0730116B2 (ja) 1995-04-05
FI104180B (fi) 1999-11-30
WO1991009059A1 (en) 1991-06-27
FI104180B1 (fi) 1999-11-30
AU639754B2 (en) 1993-08-05
PT96230B (pt) 1998-06-30
IE74708B1 (en) 1997-07-30
IE904589A1 (en) 1991-07-03
FI922847A (fi) 1992-06-18
DK0506826T3 (da) 1996-05-13
TW221675B (es) 1994-03-11
MX9203401A (es) 1992-07-01
DE69026627D1 (de) 1996-05-23
CZ635290A3 (en) 1997-08-13
DE69026627T2 (de) 1996-08-22
GR3020325T3 (en) 1996-09-30
OA09704A (en) 1993-08-30
CZ283050B6 (cs) 1997-12-17
ZA9010190B (en) 1991-08-28
NZ236511A (en) 1993-02-25
CA2071908A1 (en) 1991-06-21
NO922457L (no) 1992-06-19
NO922457D0 (no) 1992-06-19
SK635290A3 (en) 1999-06-11
US6358509B1 (en) 2002-03-19
CA2071908C (en) 2002-04-30
JPH04506359A (ja) 1992-11-05
KR960016862B1 (ko) 1996-12-23
HUT64568A (en) 1994-01-28
HU9202073D0 (en) 1992-09-28
PT96230A (pt) 1991-10-15
MY106507A (en) 1995-06-30
SK279933B6 (sk) 1999-06-11
FI922847A0 (fi) 1992-06-18
KR920703642A (ko) 1992-12-18
EP0506826B1 (en) 1996-04-17
IL96714A0 (en) 1991-09-16
AU7176291A (en) 1991-07-18
ATE136906T1 (de) 1996-05-15

Similar Documents

Publication Publication Date Title
ES2085983T3 (es) Antagonistas de anticuerpos de la interleuquina-4 humana.
DE122008000030I1 (de) Therapeutische Zusammensetzungen die monoklonale Antikörper enthalten gegen den menschlichen Rezeptor für epidermalen Wachstumsfaktor
ATE249476T1 (de) Cyclin d1 und seine cdna
DK0760857T3 (da) Receptor for onkostatin M
DE240975T1 (de) Menschliches gamma-interferon-spezifisches rezeptorprotein, antikoerper gegen dieses protein, verfahren zur herstellung dieses proteins und dieses antikoerpers und dieses protein und diesen antikoerper enthaltende zusammensetzungen.
ATE226247T1 (de) Menschliche neuronale nikotin-acetylcholin- rezeptor-verbindungen und methoden ihres einsatzes
ATA328286A (de) Zell-linien und verfahren zur herstellung von humanen monoklonalen antikörpern sowie kit und verfahren zur bestimmung der anwesenheit von p.aeruginosa
DE69115917D1 (de) Humane gammainterferonantagonisten
IT1207589B (it) Composizione di anticorpi monoclonali umani cross-protettivi.
DE3867537D1 (de) Mischung von monoklonalen antikoerpern zur bestimmung der creatinkinaseaktivitaet.
ATE48037T1 (de) Verfahren und reagenz zur verwendung zur bestimmung von pivka-ii.
TR200102877T2 (tr) İmmünoglobulinin kendi yüksek afinite reseptörüne bağlanmasını inhibe eden antikorlara karşı anti-idiotipik antikorlar.
ATE41414T1 (de) Acetaminophenanaloge, 1-antigene und -antikoerper.
DE3884646D1 (de) Humanes Karcinom-assoziertes Antigen und an dieses Antigen bindende Antikörper.
ES2052913T3 (es) Ensayo inmunoquimico en cuanto al factor estimulante de colonias de granulocitos-macrofagos.
DE69216408D1 (de) Charakterisierung oder bestimmung der menge von säugerzellen mittels antikörpern

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 506826

Country of ref document: ES